RE:RE:July PresentationCiao wrote: EbbFlow88,
Perhaps they can fast track clinical studies with the alternate carriers.
Hopefully. I remember the BG/COq10 took a while with proving stability and bioavailability. I realize the cost issue with it and the need for the other NCC's.
This is/has been a nice addition to the pipeline and the most near-term catalyst to additional cash flows. Since i began investing in CZO in 2017 this was the main player in near term pipeline. It has yet to come to market and now we've taken steps backwards.
Going forward, there is also risk of dilution to fund YBG in Germany, along with the potential for underwhelming cholesterol results. It feels like a lot is riding on 2021/Q1 2022.
It's frustrating becuase they could further decrease risk as they have in the past by increasing short term cash flows in the functional drink to fund the bigger projects in our pipeline.